ASH2020: Ruxolitinib is a major step forward for patients with chronic GVHD – where corticosteroids are inadequate
/ BestPractice Nordic Redaksjon
ASH2020: Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%
/ BestPractice Nordic Redaksjon
ASH2020: Promising results for treatment of AML
/ BestPractice Nordic Redaksjon